Global Bentonite Market Research Report, Share, and Forecast to 2025Posted by rekha on November 26th, 2019 “The Global Pancreatic Cancer Therapeutics Market estimated to grow at notable growth rate to reach US$ 1,343.8 Mn by 2025. The market has significant opportunities over the forecast period 2019-2025 due to surge in prevalence of pancreatic cancer across the globe.” Precision Business Insights (PBI) in its report titled “Global Pancreatic Cancer Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. The global pancreatic cancer treatment market projected to reach US$ 1,343.8 Mn by 2025 and the key factor prompting the escalation of market revenue is rise in prevalence of pancreatic cancer in various countries across the globe. For instance, as per World Cancer Research Fund 2018, approximately 460,000 new cases diagnosed with pancreatic cancer and the disease 12th most commonly occurring cancer in men and 11th most commonly occurring cancer in women. Moreover, increase in R&D activities for the development of novel therapeutics for pancreatic cancer treatment, raise in funding from public and private sectors for R&D activities, rise in awareness about cancer diseases among the population, and favorable reimbursement policies are anticipated to boost the global pancreatic cancer treatment market. However, high cost and adverse effects associated with long term administration of drugs, lack of sophisticated healthcare infrastructure in underdeveloped countries for early stage disease diagnosis, and patent expiry of blockbuster drugs are hinder the global pancreatic cancer treatment market. Global pancreatic cancer treatment market segmented on the basis of treatment type, cancer type, distribution channel, and region Request for Sample Report @ https://www.precisionbusinessinsights.com/request-sample?product_id=17087 Immunotherapy Dominates the Global Pancreatic Cancer Therapeutics Market Based on treatment type, global pancreatic cancer treatment market segmented into chemotherapy, targeted therapy, and others. Targeted therapy projected to dominate the market over the forecast years owing to innovation of newer therapeutics by the market players. For instance, in October 2018, AstraZeneca and Merck & Co., Inc.granted orphan drug designation (ODD) by USFDA for Lynparza (olaparib), a targeted drug used for the treatment of pancreatic cancer. Moreover, limited adverse effects with targeted therapy over other existed therapies and surge in demand for targeted therapy by healthcare professionals also surge the market over the forecast timeframe. However, chemotherapy drugs also have significant growth rate over the forecast years due to patent expiration of block buster drugs and launch of generics into market. North America Dominates the Global Pancreatic Cancer Therapeutics Market PBI’s global pancreatic cancer treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America dominated the global pancreatic cancer treatment market from 2014-2018 and expected to grow at significant growth rate over 2019-2025 owing to frequent FDA approval for the pancreatic cancer treatment drugs. For instance, in October 2015, Ipsen Biopharmaceuticals, Inc. received FDA approval for Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with metastatic pancreatic cancer. Europe pancreatic cancer treatment market expected to surge at significant CAGR over the forecast years owing to entry of market players into emerging countries, surge in prevalence of pancreatic disease, and increase in medical tourism in the region. Launch of newer products, frequent product approvals, and strategic alliances are the key strategies adopted by market players Global pancreatic cancer treatment market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For instance. In January 2017, Tempus, Inc. and University of Michigan collaborated to for the development of novel pancreatic cancer therapeutics Key player’s profiles in the report are F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Merck & Co., Inc. (USA), Pfizer, Inc. (USA), Eli Lilly and Company (USA), Boehringer Ingelheim GmbH (Germany), Celgene Corporation (USA), Amgen, Inc. (USA), Tempus, Inc. (USA), and Ipsen (France) Detailed Segmentation By Treatment Type o Chemotherapy
o Targeted therapy o Others By Cancer Type o Exocrine pancreas cancer o Endocrine pancreas cancer By Distribution Channel o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies Geography o North America
o Europe
o Asia-Pacific
o Latin America
o Middle East and Africa (MEA)
For more information: https://www.precisionbusinessinsights.com/market-reports/global-pancreatic-cancer-therapeutics-market/ Like it? Share it! More by this author |